The F8 formulation is 8 times more concentrated than Egrifta and 2 times more concentrated than the current F4 formulation, Egrifta SV.
Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
A new tablet formulation of SMA treatment Evrysdi (risdiplam) may give patients more "freedom and independence," a Genentech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback